| [1] Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397-405.[2] 杨发誉,葛香连,谷峰.新型靶向基因组编辑技术研究进展[J].中国生物工程杂志,2014,34(2):98-103.[3] Weatherall DJ, Clegg JB.Thalassemia--a global public health problem.Nat Med. 1996;2(8):847-849.[4] Zeng YT, Huang SZ. Disorders of haemoglobin in China. J Med Genet. 1987;24(10):578-583.[5] Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol. 1998;11(1):127-146.[6] Ribeil JA, Arlet JB, Dussiot M, et al. Ineffective erythropoiesis in β -thalassemia. Scientific World Journal. 2013;2013: 394295.[7] Finotti A, Breda L, Lederer CW, et al. Recent trends in the gene therapy of β-thalassemia.J Blood Med. 2015;6:69-85.[8] Weatherall DJ,Clegg JB.The Thalassemia Syndrome[M].3rd ed.Oxford:Blackwell Scientific Publication,1981.[9] Wheeler K. Manual of Pediatric Hematology and Oncology. Arch Dis Child. 1995; 73(4):381.[10] Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38(4):360-366.[11] Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin Hematol. 2001;38(4):382-392.[12] Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998; 22(1):1-6.[13] Luzzatto L, Goodfellow P. Sickle cell anaemia. A simple disease with no cure. Nature. 1989;337(6202):17-18.[14] King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20): 3089-3094.[15] Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better. J Allergy Clin Immunol. 2010; 126(3):602-610.[16] Sadelain M. Genetic treatment of the haemoglobinopathies: recombinations and new combinations. Br J Haematol. 1997; 98(2):247-253.[17] Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872.[18] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920.[19] Morishima T, Watanabe K, Niwa A, et al. Neutrophil differentiation from human-induced pluripotent stem cells. J Cell Physiol. 2011;226(5):1283-1291.[20] Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science. 1994;265(5175):1098-1101.[21] Choi KD, Vodyanik M, Slukvin II. Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc. 2011;6(3):296-313.[22] Wang J, Chao F, Han F, et al. PET demonstrates functional recovery after transplantation of induced pluripotent stem cells in a rat model of cerebral ischemic injury. J Nucl Med. 2013;54(5):785-792.[23] Asgari S, Moslem M, Bagheri-Lankarani K, et al. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev. 2013;9(4):493-504.[24] Takebe T, Zhang RR, Koike H, et al. Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. Nat Protoc. 2014;9(2):396-409.[25] Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318(5858):1920-1923.[26] Harrison MM, Jenkins BV, O'Connor-Giles KM, et al. A CRISPR view of development. Genes Dev. 2014;28(17): 1859-1872.[27] 王令,张存芳,张智英.锌指核酸酶在基因组定向修饰中的应用[J]. 中国生物化学与分子生物学报,2009,25(7):585-589.[28] Plavec I, Papayannopoulou T, Maury C, et al. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood. 1993;81(5):1384-1392.[29] Chang JC, Liu D, Kan YW. A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression. Proc Natl Acad Sci U S A. 1992; 89(7):3107-3110.[30] Fischer A, Hacein-Bey Abina S, Touzot F, et al. Gene therapy for primary immunodeficiencies. Clin Genet. 2015;88(6): 507-515.[31] Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355-364.[32] Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.[33] Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239.[34] Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008; 19(10):979-990.[35] Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2240-2248.[36] Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.[37] Porteus MH, Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol. 2005;23(8):967-973.[38] Kim YG, Chandrasegaran S. Chimeric restriction endonuclease. Proc Natl Acad Sci U S A. 1994; 91(3):883-887.[39] Merlin C, Beaver LE, Taylor OR, et al. Efficient targeted mutagenesis in the monarch butterfly using zinc-finger nucleases. Genome Res. 2013;23(1):159-168.[40] Wu J, Kandavelou K, Chandrasegaran S. Custom-designed zinc finger nucleases: what is next. Cell Mol Life Sci. 2007; 64(22):2933-2944.[41] Chang CJ, Bouhassira EE. Zinc-finger nuclease-mediated correction of α-thalassemia in iPS cells. Blood. 2012;120 (19):3906-3914.[42] Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood. 2011;118(17): 4599-4608.[43] Soldner F, Laganière J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146(2): 318-331.[44] Ma N, Shan Y, Liao B, et al. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs). J Biol Chem. 2015;290(19): 12079-12089.[45] Sander JD, Dahlborg EJ, Goodwin MJ, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods. 2011;8(1):67-69.[46] Händel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther. 2011;11(1): 28-37. [47] Mussolino C, Cathomen T. TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol. 2012;23(5): 644-650.[48] Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326(5959):1509-1512.[49] Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. 2011;29(8):731-734.[50] Wang H, Hu YC, Markoulaki S, et al. TALEN-mediated editing of the mouse Y chromosome. Nat Biotechnol. 2013;31(6): 530-532.[51] Ma N, Liao B, Zhang H, et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells. J Biol Chem. 2013;288(48):34671-34679.[52] Sun N, Zhao H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng. 2014;111(5): 1048-1053.[53] Ding Q, Lee YK, Schaefer EA, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell. 2013;12(2):238-251.[54] Lin G, Zhang K, Li J.Application of CRISPR/Cas9 Technology to HBV.Int J Mol Sci. 2015;16(11):26077-26086.[55] Mojica FJ, Díez-Villaseñor C, García-Martínez J, et al. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology. 2009;155(Pt 3): 733-740.[56] Brouns SJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. 2008;321 (5891): 960-964.[57] Pougach K, Semenova E, Bogdanova E, et al. Transcription, processing and function of CRISPR cassettes in Escherichia coli. Mol Microbiol. 2010;77(6):1367-1379.[58] Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821.[59] 白敏,李崎,邵艳姣,等.利用CRISPR/Cas9技术构建定点突变小鼠品系[J].遗传,2015,37(10):1029-1035.[60] Xie F, Ye L, Chang JC, et al. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24(9): 1526-1533.[61] González F, Zhu Z, Shi ZD, et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell. 2014;15(2):215-226. [62] Ramalingam S, Annaluru N, Chandrasegaran S. A CRISPR way to engineer the human genome. Genome Biol. 2013; 14(2):107.[63] Wu Y, Liang D, Wang Y, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell. 2013; 13(6): 659-662.[64] Long C, McAnally JR, Shelton JM, et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science. 2014;345(6201): 1184-1188.[65] Wu Y, Zhou H, Fan X, et al. Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res. 2015;25(1):67-79.[66] Guan Y, Ma Y, Li Q, et al. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med. 2016; 8(5):477-488.[67] Liang P, Xu Y, Zhang X, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015; 6(5):363-372. |
.jpg)
.jpg)